AbbVie (ABBV) delivered impressive financial results for the first quarter of 2025. Investors responded enthusiastically, pushing AbbVie’s stock up 3.15% on the announcement day and 8.70% for ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including business strategies shaping the future of healthcare and three major health news trends. NEW YORK, March 7 ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including business strategies shaping the future of healthcare and three major health news trends.

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant ...

AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative colitis, building on Health Canada's prior approval. This significant ...

The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative options ...

So, on February 7, 2025, the FDA approved Emblaveo in combination with metronidazole for the treatment of patients with complicated intra-abdominal infections. Also, a week later, ...

Emblaveo was developed in partnership with Pfizer. AbbVie has commercialization rights to the drug in the U.S and Canada; Pfizer is responsible for the antibiotic’s commercialization in the rest ...

Emblaveo is supplied in a single-dose vial as a lyophilized powder containing 1.5g of aztreonam and 0.5g of avibactam that requires reconstitution and dilution prior to IV infusion.

Michael’s elevation came days after AbbVie received FDA approval for their treatment Emblaveo, which targets intra-abdominal infections. As for Gonzalez, he will officially leave the board of ...

The FDA has approved aztreonam and avibactam (Emblaveo) in combination with metronidazole for adults who have limited or no alternative options for the treatment of complicated intra-abdominal ...